OncoMax?s renal cell carcinoma research awarded special prize in Europe

Extensive research conducted by Russian company OncoMax in the field of cancer therapy was awarded a special prize last month at a European symposium in France

Extensive research conducted by Russian company OncoMax in the field of cancer therapy was honored with a special First Prize award last month at the 5th European Multidisciplinary Meeting for Urological Cancer (EMUC), announced the official website of Russian Venture Company (RVC), Russia?s fund of funds for innovation whose subsidiary participated in OncoMax?es first round of funding three years ago. The research is said to have proven that using the OM-RCA-01, a monoclonal antibody developed most recently by OncoMax and capable of blocking the FGF receptor, can inhibit blood vessel growth in a kidney tumor. ?This elegant study has a great practical importance and answers the question how to overcome drug resistance in kidney cancer therapy,? emphasized Dr. Martin Spahn, the co-chairman of the Organizing Committee, during the award presentation...